Scholarlink

<p>Mindfulness-Based Stress Reduction (MBSR) improves well-being in acute myocardial infarction (AMI) patients, but its molecular cardioprotective mechanisms are unclear. In this prospective pilot study, 51 post-PCI AMI patients (17 MBSR plus standard therapy, 34 controls) were assessed for inflammatory markers (CRP, IL-6, PCT), echocardiography, and functional capacity at baseline and 6 months. Genome-wide DNA methylation profiling in a subgroup (<i>n</i> = 5/group) assessed changes from baseline to 6 months within MBSR and compared groups at the 6-month follow-up. At follow-up, the MBSR group showed greater reductions in CRP, IL-6, and PCT (adjusted <i>P</i> = 0.001, &lt; 0.001, 0.003), alongside improved left ventricular ejection fraction, global longitudinal strain, wall motion score index, and 6-minute walk distance; all remained significant after false discovery rate correction (all q &lt; 0.05). MBSR induced widespread DNA methylation changes (7,665 intra-group and 7,791 inter-group differentially methylated sites), which were nominally enriched in pathways related to immune response, inflammation, oxidative stress, and neuroendocrine (HPA axis) regulation. Exploratory uncorrected analysis linked BRD4 hypermethylation with lower CRP (ρ=-0.601) and improved GLS (ρ = 0.802), and PTTG1IP hypomethylation with improved LVEF (ρ = 0.717). These findings suggest MBSR modulates the DNA methylome within a novel “epigenetic-inflammatory-cardiac functional axis”, providing a mechanistic framework for its cardioprotective effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DNA methylation mediates MBSR induced cardioprotection in patients after PCI

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Mengyuan Xiong,
  • Xingkui Dou,
  • Jifa Tao,
  • Fei Hu,
  • Pan Jing,
  • Zhao Zhao,
  • Hongyan Cai,
  • Zhao Hu,
  • Min Zhang

摘要

Mindfulness-Based Stress Reduction (MBSR) improves well-being in acute myocardial infarction (AMI) patients, but its molecular cardioprotective mechanisms are unclear. In this prospective pilot study, 51 post-PCI AMI patients (17 MBSR plus standard therapy, 34 controls) were assessed for inflammatory markers (CRP, IL-6, PCT), echocardiography, and functional capacity at baseline and 6 months. Genome-wide DNA methylation profiling in a subgroup (n = 5/group) assessed changes from baseline to 6 months within MBSR and compared groups at the 6-month follow-up. At follow-up, the MBSR group showed greater reductions in CRP, IL-6, and PCT (adjusted P = 0.001, < 0.001, 0.003), alongside improved left ventricular ejection fraction, global longitudinal strain, wall motion score index, and 6-minute walk distance; all remained significant after false discovery rate correction (all q < 0.05). MBSR induced widespread DNA methylation changes (7,665 intra-group and 7,791 inter-group differentially methylated sites), which were nominally enriched in pathways related to immune response, inflammation, oxidative stress, and neuroendocrine (HPA axis) regulation. Exploratory uncorrected analysis linked BRD4 hypermethylation with lower CRP (ρ=-0.601) and improved GLS (ρ = 0.802), and PTTG1IP hypomethylation with improved LVEF (ρ = 0.717). These findings suggest MBSR modulates the DNA methylome within a novel “epigenetic-inflammatory-cardiac functional axis”, providing a mechanistic framework for its cardioprotective effects.